Combined IL-21 and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques
|
|
- Pauline Blankenship
- 6 years ago
- Views:
Transcription
1 Combined and IFNα treatment limits inflammation and delay viral rebound in ART-treated, SIV-infected macaques Mirko Paiardini Associate Professor, Emory University School of Medicine Yerkes National Primate Research Center IAS Cure & Cancer Forum Paris, France
2 Interleukin-21 treatment in SIV-infected RMs o Th17 cell maintenance is severely impaired in the absence of (Nurieva, Nature 27; Korn, Nature 27; Yang, Nature 28) o Paucity of -producing CD4+ T cells is associated with Th17 depletion in SIVinfected RMs (Micci, Blood 212); o Loss of function of intestinal IL-17 producing cells contributes to inflammation and viral persistence in SIV-infected RMs (Ryan, PLoS Pathogens 216) o treatment in acute SIV infection preserves Th17 cells and reduces microbial translocation (Micci, PLoS Pathogens 214) o treatment in ART-suppressed, SIV-infected RMs reduces residual inflammation and viral persistence (Micci, J Clin Invest 215)
3 limits intestinal T cell activation and proliferation Treated Treated %CD4 HLA-DR + CD38 + T cells RB P=.3 P=.11 P<.1 P<.1 P=.2 %CD8 HLA-DR + CD38 + T cells RB P=.21 P=.2477 P<.1 P<.1 P=.12 days on ART pre-art days on ART pre-art Average fold change vs day 58 (pre-art) %CD4 + Ki-67 + T cells RB o o 2 1 Average fold change vs day 58 (pre-art) P=.3 P=.17 day 58 day 84 day 256 Treated P<.1 But modestly reduces plasma P=.19 P=.21 P=.12 viremia upon ART-interruption No differences in timing of rebound No significant differences in viremia at any experimental points Micci L, J Clin Invest 215
4 Rationale and Study design Phase 1 Gr. 1: ART; #7 RMs Gr. 2: ART+IL21+IFN-α; #14 RMs d35 p.i. r r IFN-α SIVmac239 ART (TDF+FTC+DTG) Weeks Relative to infection LOD: 3 copies/ml A: ART Inflammation Antiviral functions B: ART + + IFNα Inflammation Antiviral functions Time Normalized Read Count 15 1 Time p<.1 + TX IFIT2 MX1 OAS2 MX2 SAMHD1 STAT1 IFIT3 IFI16 GBP1 IFI6 ISG2 ISG15 OAS3 OASL OAS1 IFI27 IRF7 CXCL1 TRIM5 IFIH1 CCL8 APOBEC3G STAT2 IFIT5 IFI44 RTP4 CHMP5 ISG expression by RNAseq in total PBMCs
5 +IFNα treated RMs maintain low levels of activation on ART CD4+ T cells CD8+ T cells PB %CD4 + Mem. HLA-DR + CD38 + T cells PB * + TX ** ** ** %CD8 + Mem. HLA-DR + CD38 + T cells PB * + Tx Days Post Infection Days Post Infection RB %CD4 + Mem. HLA-DR + CD38 + T cells RB Days Post Infection + TX %CD8 + Mem. HLA-DR + CD38 + T cells RB Days Post Infection Treated
6 Infectious units per million (IUPM) In fe c tio u s u n its p e r m ilio n (IU P M ) C D 4 T c e lls (L N ) +IFNα treated RMs show reduced viral on ART controls + IFNα + TX RPk11 & RNa12 (PTCs) excluded Rectal biopsies CD4+ T cells from LN c A R T P =. 9 SIVmac 239 DNA copies per 1 6 Tot. CD4 (RB) pre-art P=.1 P=.6 P=.1 on-art IF N + IFNα c o n o Longitudinal measurements including post but pre IFNα are pending Additional QVOA analyses in purified CD4+ T cells from LN are pending d35 IL21+ d35 CTRS d37 IL21+ d37 CTRS d a d 3 7 c trs
7 percent of viremic RMs 1 +IFNα treated RMs show delayed and RPk11 & RNa12 excluded (PTCs) reduced viral rebound after ATI plasma viral load betweem +peg-ifn a vs. Gr. 1: ART; #7 RMs Gr. 2: ART+IL21+IFN-α; #14 RMs Viral Rebound proportions post-art cessation 5/5 d35 p.i. r r Phase 1 SIVmac239 P=.2 ART (TDF+FTC+DTG) 2/8 + peg- TX IFN-α Phase 2 Viral rebound Phase 3 P=.5 Necropsy Weeks Relative to infection cut-off: 2 copies/ml 2 2 Control /8 IL21+peg-IFNα Days after ART interruption days post-art interruption 7/8 7/8 Plasma SIVmac 239 RNA copies/ml d6 peg+ Tx P=.4 for time window from day 6 to 44 ATI; 1.29 log 1 mean difference d6 controls d9 peg+ Tx P<.1 P<.1 peg- P<.1 d9 controls d13 peg+ Tx d13 controls d2 peg+ Tx d2 controls d3 peg- Tx d3 controls d44 peg-infa Tx. 44 d44 controls Kruskal-Wallis test: P=.9-3 groups separated Measures P=.2 - of Tx. vs. viral CTRS persistence post P=.25 - IgFc- Tx. vs. peg- Tx. ATI are pending What is happening after IFNα treatment has been discontinued? day 6 to 44: 1.29 log 1 mean difference
8 Preliminary conclusions + IFNα administration resulted in: Reduced mucosal and systemic immune activation Reduced cell-associated SIV-DNA in GI tract Delayed and reduced viral rebound post ATI (still during IFNα treatment) IFNα treatment was not associated with deleterious effects on T cell levels or immune activation, either on ART or after ATI Multiple immunologic and virologic parameters (including replication competent virus) are pending (longitudinal, blood and tissues) Impact on viral persistence after discontinuation of IFNα needs to be determined
9 Acknowledgments Paiardini Lab *Luca Micci Justin Harper *Sara Paganini Colin King Hong Wong Maria Pino Kristina Ortiz Emory Genomic Core Steven Bosinger Greg Tharp Nirav Patel NCI/Frederick Jeffrey Lifson Jacob Estes CASE Western Rafick Sekaly Susan Ribeiro Michael Lederman Gilead/ViiV Romas Geleziunas Jim Demarest Support NIH/NIAID amfar Emory CFAR Qura Therapeutics Emory - YNPRC Barbara Cervasi Guido Silvestri Paul Johnson Stephanie Ehnert Sherrie Jean Elizabeth Strobert U. Of Lafayette Francois Villinger *Former members Post doc positions available (mirko.paiardini@emory.edu)
Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques
Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques Luca Micci, Emory University Emily S. Ryan, Emory University Rémi Fromentin, Université de Montréal Steven
More informationCTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence
IAS 2015 Towards an HIV Cure symposium Vancouver CTLA-4-expressing CD4 T cells are critical contributors to SIV viral persistence Colleen McGary Paiardini lab Emory University HIV reservoir prevents eradication
More informationJAK3 inhibitor administration in vivo in chronically SIV Infected Rhesus Macaques
JAK3 inhibitor administration in vivo in chronically SIV Infected Rhesus Macaques preferentially depletes NK Cells Ladawan Kowawisatsut 1 Kovit Pattanapanyasat 1 Aftab A. Ansari 2 1 Department of Immunology
More informationImpact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir
Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Adam Capoferri, Juan Carlos Ramos, Daniel Xu, Daniel I.S. Rosenbloom, Janet D. Siliciano, Robert F. Siliciano, Ariela
More informationWorking Group#1: Trial Endpoints, Biomarkers & Definitions
Working Group#1: Trial Endpoints, Biomarkers & Definitions Forum HIV Cure Project: Focus on The Regulatory Pathway June 17, 2014 www.hivforum.org Comments from co-chairs john mellors and mike miller www.hivforum.org
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full//49/eaao4/dc Supplementary Materials for TLR agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral
More informationEradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD
Eradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD Conflicts of Interest The pending clinical trials discussed here are funded by grant awards from Gilead
More informationWith over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
More informationEstablishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
More informationInves&gación básica y curación del VIH-1
Inves&gación básica y curación del VIH-1 Javier Mar&nez-Picado 24 th Conference on Retroviruses and Opportunis6c Infec6ons UNIVERSITAT DE VIC Empezamos bien cart: How Early is Early Enough? Sáez-Cirion
More informationModule R: Recording the HIV Reservoir
Module R: Recording the HIV Reservoir Satish K. Pillai, Ph.D. MODULE LEADER Satish Pillai amfar Institute for HIV Cure Research Module R Team Michael Busch Timothy Henrich Sheila Keating Sulggi Lee Henry
More informationInnovative diagnostics for HIV, HBV and HCV
Innovative diagnostics for HIV, HBV and HCV Dan Otelea National Institute for Infectious Diseases Bucharest, Romania Disclaimer No conflicts of interest Innovative diagnostics for HIV, HBV and HCV - is
More informationCan HIV be cured? (how about long term Drug free remission?)
Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting 27-28 October 2010 Luxemburg HAART can control HIV, cannot eradicate it Life
More informationPD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques
Brief report Related Commentary, page 1611 PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques Ravi Dyavar Shetty, 1 Vijayakumar Velu,
More informationClinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX
Clinical Development of ABX464, drug candidate for HIV Functional Cure Jean-Marc Steens, MD Chief Medical Officer ABIVAX 1 DECLARATION OF CONFLICT OF INTEREST GSK ABIVAX 2 ABX464: Mechanism of Action ABX464
More informationAvailability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys
Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys Nichole R. Klatt, Emory University Francois Villinger, Emory University Pavel Bostik, Emory
More informationNovel Approaches for the Assessment of the In Vivo Residual Virus Pool and Viral Eradication Strategies in SIV-infected Rhesus Macaques
Towards an HIV Cure Pre-Conference Symposium 20 & 21 July 2012 Novel Approaches for the Assessment of the In Vivo Residual Virus Pool and Viral Eradication Strategies in SIV-infected Rhesus Macaques Gregory
More informationCopyright information:
Reduced Simian Immunodeficiency Virus Replication in Macrophages of Sooty Mangabeys Is Associated with Increased Expression of Host Restriction Factors Kiran Mir-Hudgeons, Emory University Maud Mavigner,
More informationSUPPLEMENTARY INFORMATION. Divergent TLR7/9 signaling and type I interferon production distinguish
SUPPLEMENTARY INFOATION Divergent TLR7/9 signaling and type I interferon production distinguish pathogenic and non-pathogenic AIDS-virus infections Judith N. Mandl, Ashley P. Barry, Thomas H. Vanderford,
More informationCD4 Depletion in SIV-Infected Macaques Results in Macrophage and Microglia Infection with Rapid Turnover of Infected Cells
CD4 Depletion in SIV-Infected Macaques Results in Macrophage and Microglia Infection with Rapid Turnover of Infected Cells Luca Micci, Emory University Xavier Alvarez, Tulane University Robin I. Iriele,
More informationThe Role of B Cell Follicles in HIV Replication and Persistence
The Role of B Cell ollicles in HIV Replication and Persistence Elizabeth Connick, M.D. Professor of Medicine Chief, Division of Infectious Diseases University of Arizona July 17, 2016 IAS 2016 Towards
More informationEarly treatment of SIV plus macaques with an alpha(4)beta(7) mab alters virus distribution and preserves CD4(+) T cells in later stages of infection
Early treatment of SIV plus macaques with an alpha(4)beta(7) mab alters virus distribution and preserves CD4(+) T cells in later stages of infection Philip J. Santangelo, Emory University Claudia Cicala,
More informationSUPPLEMENTAL INFORMATIONS
1 SUPPLEMENTAL INFORMATIONS Figure S1 Cumulative ZIKV production by testis explants over a 9 day-culture period. Viral titer values presented in Figure 1B (viral release over a 3 day-culture period measured
More informationApproaching a Cure Daniel R. Kuritzkes, MD
Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria
More informationHIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies
HIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies 10 th INTEREST CONFERENCE 2016, 3-6 TH May 2016, Yaoundé, Cameroon Cissy Kityo 1 ; Thomas Schacker 2 ; Francis Ssali 1 ; Jeffrey
More informationViral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection
Viral Reservoirs and anti-latency interventions in nonhuman primate models of SIV/SHIV infection Koen Van Rompay California National Primate Research Center University of California Davis Outline Introduction
More informationCROI 2016 Review: Immunology and Vaccines
Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational
More informationProfessor Jonathan Weber
HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust
More informationHepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D
Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision
More informationPreclinical Animal Models for HIV Cure Research in Children: Scientific Knowledge Gaps
Preclinical Animal Models for HIV Cure Research in Children: Scientific Knowledge Gaps NIAID Workshop, May 22-23, 2018 Nancy L. Haigwood, Oregon Health & Science University Mississippi baby case brought
More informationAn integrated transcriptomic and functional genomic approach identifies a. type I interferon signature as a host defense mechanism against Candida
Supplementary information for: An integrated transcriptomic and functional genomic approach identifies a type I interferon signature as a host defense mechanism against Candida albicans in humans Sanne
More informationSupplementary Figures. Supplementary Figure 1. Treatment schematic of SIV infection and ARV and PP therapies.
Supplementary Figures Supplementary Figure 1. Treatment schematic of SIV infection and ARV and PP therapies. Supplementary Figure 2. SIV replication and CD4 + T cell count. (A) Log SIVmac239 copies/ml
More informationInves)gación básica y curación del VIH- 1
Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT
More informationIAS 2013 Towards an HIV Cure Symposium
In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure
More informationImpact of ART in Primary HIV infection on T cell immune exhaustion in Gut- associated lymphoid tissue: Implications for HIV persistence
Impact of ART in Primary HIV infection on T cell immune exhaustion in Gut- associated lymphoid tissue: Implications for HIV persistence THORNHILL J, MARTIN GE, HERRERA C, HOPKINS E, FIDLER S, FRATER J
More informationThe Chimpanzee Model Of HCV: Antiviral Therapy
The Chimpanzee Model Of HCV: Antiviral Therapy Antiviral Therapies in Chimpanzees PEG IFN + Ribavirin STAT C with DAA Protease Inhibitors Nucleoside analogues Polymerase Inhibitors NS5A Inhibitors Immunomodulators
More informationAlexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout
Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 + T-cell count at 96 weeks ART Alexander O.
More informationReceived 4 December 2001/Accepted 29 April 2002
JOURNAL OF VIROLOGY, Aug. 2002, p. 8433 8445 Vol. 76, No. 16 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.16.8433 8445.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. The Relationship
More informationSupplementary Information
Supplementary Information Early Treatment of SIV+ macaques with an α 4 β 7 mab alters virus distribution and preserves CD4 + T cells in later stages of infection Philip J. Santangelo Ph.D 1#*, Claudia
More informationOver thousands of years, species-specific
T1 Natural SIV Hosts: Showing AIDS the Door Ann Chahroudi, 1,2 Steven E. Bosinger, 2 Thomas H. Vanderford, 2 Mirko Paiardini, 2,3 * Guido Silvestri 2,3 * Many species of African nonhuman primates are naturally
More informationSupplementary Materials
1 Supplementary Materials Rotger et al. Table S1A: Demographic characteristics of study participants. VNP RP EC CP (n=6) (n=66) (n=9) (n=5) Male gender, n(%) 5 (83) 54 (82) 5 (56) 3 (60) White ethnicity,
More informationInconsistent HIV reservoir dynamics and immune responses following anti-pd-1 therapy
Letter to Editor (Annals of Oncology): Inconsistent HIV reservoir dynamics and immune responses following anti-pd-1 therapy in cancer patients with HIV infection E. P. Scully 1,2,3, R. L. Rutishauser 4,
More informationSevere Depletion of Mucosal CD4 + T Cells in AIDS-Free Simian Immunodeficiency Virus-Infected Sooty Mangabeys
This information is current as of September 1, 2018. References Subscription Permissions Email Alerts Severe Depletion of Mucosal CD4 + T Cells in AIDS-Free Simian Immunodeficiency Virus-Infected Sooty
More informationRecent Insights into HIV Pathogenesis and Treatment: Towards a Cure
Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of
More informationDr Jintanat Ananworanich
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationTable S1. Viral load and CD4 count of HIV-infected patient population
Table S1. Viral load and CD4 count of HIV-infected patient population Subject ID Viral load (No. of copies per ml of plasma) CD4 count (No. of cells/µl of blood) 28 7, 14 29 7, 23 21 361,99 94 217 7, 11
More informationSystem Biology analysis of innate and adaptive immune responses during HIV infection
System Biology analysis of innate and adaptive immune responses during HIV infection Model of T cell memory persistence and exhaustion Naive Ag+APC Effector TEM (Pfp, Gr.B, FasL, TNF) Ag stim. IL-2, IL-7,
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationSUPPLEMENTARY INFORMATION
` SUPPLEMENTAL FIGURES doi:10.1038/nature10003 Supplemental Figure 1: RhCMV/SIV vectors establish and indefinitely maintain high frequency SIV-specific T cell responses in diverse tissues: The figure shows
More informationIMMUNE RECONSTITUTION AND SKEWED RESPONSES AFTER ART START IN HIV INFECTED UGANDANS
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Abst#_PP_25 IMMUNE RECONSTITUTION AND SKEWED RESPONSES AFTER ART START
More informationTherapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells
Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During
More informationFunctional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4 + T Cells and Is Reverted by CD8 + Cell Depletion
Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4 + T Cells and Is Reverted by CD8 + Cell Depletion Ivona Pandrea 1,2,3, Thaidra Gaufin 4, Rajeev Gautam 4, Jan
More informationModels of HIV during antiretroviral treatment
Models of HIV during antiretroviral treatment Christina M.R. Kitchen 1, Satish Pillai 2, Daniel Kuritzkes 3, Jin Ling 3, Rebecca Hoh 2, Marc Suchard 1, Steven Deeks 2 1 UCLA, 2 UCSF, 3 Brigham & Womes
More informationAddressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting
Addressing key gaps in cure research through identification and treatment of hyperacute HIV infection in a resource-limited setting Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis
More informationThe Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial
The Impact of Immunoglobulin in Acute HIV Infection on the HIV Reservoir: A Pilot Randomized Controlled Trial Olubanke Davies Guy s & St Thomas NHS Foundation Trust BACKGROUND Immediate ART during acute
More informationDNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04)
DNA and Protein Vaccination Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660 (OA 10.04) Rashmi Jalah Human Retrovirus Pathogenesis Section, Vaccine Branch, CCR, National Cancer Institute
More informationHIV viral load testing in the era of ART. Christian Noah Labor Lademannbogen, Hamburg
HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis
More informationImpact of antiretroviral therapy on gut immunology and the HIV reservoir in elite controllers
Impact of antiretroviral therapy on gut immunology and the HIV reservoir in elite controllers Connie J Kim (Abstract #185) Session: Building Better Therapeutics November 19, 2013 10:00am HIV Elite Controllers
More informationEXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE
EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE CECILE DELILLE LAHIRI, M.D, M.SC ASSISTANT PROFESSOR DIVISION OF INFECTIOUS DISEASES MAY 18, 2016 OUTLINE Describe discrepancy between
More informationEndogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation
Sabbatucci et al. Retrovirology (2015) 12:4 DOI 10.1186/s12977-014-0132-6 RESEARCH Open Access Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral
More informationMother-to-Infant Transmission of Simian Immunodeficiency Virus Is Rare in Sooty Mangabeys and Is Associated with Low Viremia
JOURNAL OF VIROLOGY, June 2011, p. 5757 5763 Vol. 85, No. 12 0022-538X/11/$12.00 doi:10.1128/jvi.02690-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Mother-to-Infant Transmission
More informationAnimal models in HIV cure research.
Animal models in HIV cure research. Luca Micci, Yerkes National Primate Research Center Mirko Paiardini, Emory University Colleen S. McGary, Yerkes National Primate Research Center Journal Title: Journal
More informationDavid Verhoeven, Sumathi Sankaran, Melanie Silvey, and Satya Dandekar*
JOURNAL OF VIROLOGY, Apr. 2008, p. 4016 4027 Vol. 82, No. 8 0022-538X/08/$08.00 0 doi:10.1128/jvi.02164-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Antiviral Therapy during
More informationPrimate models of SIV infection: Differenct susceptibility of African green monkeys and macaques to develop AIDS
Les Pensières Animal Models, 2011 Primate models of SIV infection: Differenct susceptibility of African green monkeys and macaques to develop AIDS Michaela Müller-Trutwin Unité de Régulation des Infections
More informationThe potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies
The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies Stephen Mason Director, Discovery Virology Bristol-Myers Squibb Community Cure Workshop 2015 Sunday, Feb 22, 2015 Seattle,
More informationCan HPV, cervical neoplasia or. HIV transmission?
Interactions between HPV and HIV: STIs and HIV shedding, regulation of HPV by HIV, and HPV VLP influence upon HIV Jennifer S. Smith Department of Epidemiology pd University of North Carolina Can HPV, cervical
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationProfessor Anna Maria Geretti
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Anna Maria Geretti Institute of Infection & Global Health, University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT
More informationTherapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees
Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees Robert Lanford 1, Bernadette Guerra 1, Deborah Chavez 1, Vida L. Hodara 1, Xubin Zheng 2, Grushenka Wolfgang 3, Daniel B.
More informationPROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater
PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of
More informationTherapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
30 1, 1, 2, 3 1. ( ), 201508; 2., 200040; 3., 200032 : ( AIDS) ( HIV) 20 90,,,,,, AIDS, CD4 + T ( CTL), HIV, : ; ; Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
More informationNo Conflict of Interest
No Conflict of Interest Aging and HIV Co-Morbidities: A Challenge for Engagement in Care Maria L Alcaide M.D. Division of Infectious Diseases University of Miami Miller School of Medicine Objectives Understand
More informationPathogenesis Update Robert F. Siliciano, MD, PhD
Pathogenesis Update Robert F. Siliciano, MD, PhD Professor of Medicine and Molecular Biology and Genetics Johns Hopkins University School of Medicine Investigator, Howard Hughes Medical Institute HIV-1
More informationTherapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques
Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques Deborah Heydenburg Fuller 1,2,3 * a, Premeela Rajakumar
More informationSupervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic
More informationAntiretroviral Therapy in Simian Immunodeficiency Virus-Infected Sooty Mangabeys: Implications for AIDS Pathogenesis
Antiretroviral Therapy in Simian Immunodeficiency Virus-Infected Sooty Mangabeys: Implications for AIDS Pathogenesis Francesca Calascibetta, Emory University Luca Micci, Emory University Diane Carnathan,
More informationDamaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus Infections
Damaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus Infections Jacob D. Estes 1 *, Levelle D. Harris 2, Nichole R. Klatt 2, Brian Tabb
More informationSustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion
Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion R Gupta 1, A Abdulijawad 2, L McCoy 2, D Peppa 3, M Salgado 4, J Martinez- Picado 4, A Wensing
More informationVirus-like particle vaccine activates and promotes B cell differentiation to IgG2a producing plasma cells Qizhi Cathy Yao, M.D., Ph.D.
Virus-like particle vaccine activates and promotes B cell differentiation to IgG2a producing plasma cells Qizhi Cathy Yao, M.D., Ph.D. Molecular Surgeon Research Center Michael E. DeBakey Department of
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationSupplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.
Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,
More informationJournal of Infectious Diseases Advance Access published July 11, Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers
Journal of Infectious Diseases Advance Access published July 11, 2013 1 Effect of Antiretroviral Therapy on HIV Reservoirs in Elite Controllers Tae-Wook Chun 1,6, J. Shawn Justement 1, Danielle Murray
More informationLow immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease
Low immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease Shailesh K. Choudhary 1 *, Nienke Vrisekoop 2 *, Christine A. Jansen 2, Sigrid A. Otto 2, Hanneke
More informationI declare that I have no financial conflicts of interest
I declare that I have no financial conflicts of interest Cytotoxic T-Lymphocytes Eliminate Defective HIV Proviruses Without Impacting Infectious Reservoirs R. Brad Jones Assistant Professor The George
More informationDestruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin
Destruction of the Residual Active HIV-1 Reservoir by Env-specific Immunotoxin J. Victor Garcia-Martinez, Ph.D. University of North Carolina, at Chapel Hill IAS 2013 Towards an HIV Cure Symposium Delivering
More informationCD8+ Lymphocytes Control Viral Replication in SIVmac239-Infected Rhesus Macaques without Decreasing the Lifespan of Productively Infected Cells
CD8+ Lymphocytes Control Viral Replication in SIVmac239-Infected Rhesus Macaques without Decreasing the Lifespan of Productively Infected Cells The Harvard community has made this article openly available.
More informationAre Immune Modulators Really Needed to Cure HBV infection?
Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,
More informationDeconvolution of Heterogeneous Wound Tissue Samples into Relative Macrophage Phenotype Composition via Models based on Gene Expression
Electronic Supplementary Material (ESI) for Integrative Biology. This journal is The Royal Society of Chemistry 2017 Supplementary Information for: Deconvolution of Heterogeneous Wound Tissue Samples into
More informationPROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA
PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA SoGAT Clinical Diagnostics II 30 September / 1 October 2009, Istanbul Michael Chudy Julia Kreß C. Micha
More informationAdditional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T
September 8, 2014 Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV- Infected Subjects Treated with SB-728-T
More informationNonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response
Research article Related Commentary, page 3512 Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response Béatrice Jacquelin, 1 Véronique Mayau, 1
More informationInclusion/Exclusion Criteria
The Immunomodulatory Effects of Intensification among ART-suppressed Patients with Incomplete CD4 Recovery Peter W. Hunt, Nancy Shulman, Tim Hayes, Viktor Dahl, Ma Somsouk, Nick Funderburg, Alan L. Landay,
More information10th International Rotavirus Symposium Bangkok, Thailand
Rotavirus Host Range Restriction and Innate Immunity: Mechanisms of Vaccine Attenuation Harry Greenberg MD Stanford University 10th International Rotavirus Symposium Bangkok, Thailand 09/19/12 B dsrna
More informationMarmoset-based infectious disease research under biocontainment conditions
Marmoset-based infectious disease research under biocontainment conditions Jean Patterson, PhD Texas Biomedical Research Institute October 22 nd, 2018 West Nile virus Common marmoset found to be equivalently
More informationTarget Cell Availability, Rather than Breast Milk Factors, Dictates Mother-to-Infant Transmission of SIV in Sooty Mangabeys and Rhesus Macaques
Target Cell Availability, Rather than Breast Milk Factors, Dictates Mother-to-Infant Transmission of SIV in Sooty Mangabeys and Rhesus Macaques Ann Chahroudi, Emory University Emily Cartwright, Emory University
More informationBEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy
BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy We are pleased to announce that the National Institutes of Health (NIH) has awarded nearly $23 million to co-principal
More informationLa risposta immune all infezione da virus ebola. Chiara Agrati, PhD
La risposta immune all infezione da virus ebola Chiara Agrati, PhD Pathogenetic mechanisms This virus infection is able to: - disable the immune system, preventing an effective protective immune response
More informationIAS 2016 Towards an HIV Cure Symposium Durban, South Africa.
Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals treated during acute HIV infection Eugène Kroon, Jintanat Ananworanich,
More informationCTLA-4 + PD-1 Memory CD4 + T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques
Article CTLA-4 + PD-1 Memory CD4 + T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques Graphical Abstract Authors Colleen S. McGary, Claire
More information